Background. Although early stage non-small cell lung cancer (NSCLC) has an excellent outcome and correlated with good long-term survival, up to 15 percent of patients still relapse postoperatively and die. This study is conducted to identify prognostic factors that may affect the long-term survival in completely resected N0 NSCLC. Methods. Medical records of 124 patients with completely resected N0 NSCLC were retrospectively reviewed. Prognostic factors affecting long-term survival were analyzed by the Kaplan-Meier method and Cox proportional hazards analysis. Results. Overall five-year survival rate was 48 percent. Multivariable analysis revealed stage of disease, tumor necrosis, tumor recurrence, brain metastasis, adrenal metastases, and skin metastases as significant prognostic factors affecting long-term survival. The hazard ratio (HR) of tumor necrosis, tumor recurrence, brain metastasis, adrenal metastases, and skin metastases was 2.0, 2.3, 7.6, 4.1, and 8.3, respectively, and all P values were less than 0.001. Conclusions. Our study shows stage of disease, tumor necrosis, tumor recurrence, brain metastasis, adrenal metastasis, and skin metastasis as the independent prognostic factors of long-term survival in pathological N0 NSCLC. Early stage NSCLC patients without nodal involvement or presented with tumor necrosis should benefit from adjuvant chemotherapy, and sites of metastasis could predict the long-term survival as described. 1. Introduction The curative treatment for early stage non-small cell lung cancer (NSCLC) patients without nodal involvement is surgery alone; however, some pathological characteristics may be associated with poor prognostic of long-term survival. Overall 5-year survival rates in completely resected stages IA and IB NSCLC range from 67 to 89% and from 57 to 75%, respectively; therefore, there are some poor prognostic factors that affect the overall survival despite presenting in the same stage [1–4]. Recently, some prognostic factors such as intratumoral blood vessel invasion (IVI), intratumoral lymphatic invasion (ILI), visceral pleural invasion, tumor size, and serum level of carcinoembryonic antigen (CEA), have been proposed in order to identify poor prognostic factors providing beneficial adjuvant chemotherapy for stage I NSCLC patients. Some studies showed that the strong poor prognostic factors in these patients are IVI and ILI [1, 5–7]. The purpose of this study is to identify prognostic factors associated with poor prognosis in overall survival in completely resected N0 NSCLC patients. 2. Patients and Methods
References
[1]
W. Liu, D. Morito, S. Takashima et al., “Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development,” PLoS ONE, vol. 6, no. 7, Article ID e22542, 2011.
[2]
T. Goya, H. Asamura, H. Yoshimura et al., “Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study,” Lung Cancer, vol. 50, no. 2, pp. 227–234, 2005.
[3]
K. Inoue, M. Sato, S. Fujimura et al., “Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993,” Journal of Thoracic and Cardiovascular Surgery, vol. 116, no. 3, pp. 407–411, 1998.
[4]
H. Asamura, T. Goya, Y. Koshiishi et al., “A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers,” Journal of Thoracic Oncology, vol. 3, no. 1, pp. 46–52, 2008.
[5]
H. Matsuguma, R. Nakahara, S. Igarashi et al., “Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis,” Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 1, pp. 44–49, 2008.
[6]
T. Tsuchiya, S. Akamine, M. Muraoka et al., “Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy,” Lung Cancer, vol. 56, no. 3, pp. 341–348, 2007.
[7]
J.-I. Ogawa, T. Tsurumi, S. Yamada, S. Koide, and A. Shohtsu, “Blood vessel invasion and expression of sialyl Lewis(x) and proliferating cell nuclear antigen in Stage I non-small cell lung cancer: relation to postoperative recurrence,” Cancer, vol. 73, no. 4, pp. 1177–1183, 1994.
[8]
P. Goldstraw, Ed., Staging Manual in Thoracic Oncology, John Wiley & Sons, Denver, Colo, USA, 2009.
[9]
P. Goldstraw, “Editorial: The 7th edition of TNM in lung cancer: what now?” Journal of Thoracic Oncology, vol. 4, no. 6, pp. 671–673, 2009.
[10]
W. D. Travis, E. Brambilla, H. K. Muller-Hermelink, and C. C. Harris, Eds., World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, IARC Press, Lyon, France, 2004.
[11]
A. Yilmaz, S. S. Duyar, E. Cakir et al., “Clinical impact of visceral pleural, lymphovascular and perineural invasion in completely resected non-small cell lung cancer,” European Journal of Cardio-Thoracic Surgery, vol. 40, no. 3, pp. 664–670, 2011.
[12]
T. T. V. Pechet, S. R. Carr, J. E. Collins, H. E. Cohn, and J. L. Farber, “Arterial invasion predicts early mortality in stage I non-small cell lung cancer,” Annals of Thoracic Surgery, vol. 78, no. 5, pp. 1748–1753, 2004.
[13]
F. Shoji, A. Haro, T. Yoshida et al., “Prognostic significance of intratumoral blood vessel invasion in pathologic stage IA non-small cell lung cancer,” Annals of Thoracic Surgery, vol. 89, no. 3, pp. 864–869, 2010.
[14]
M. J. Schuchert, L. Schumacher, A. Kilic et al., “Impact of angiolymphatic and pleural invasion on surgical outcomes for Stage i non-small cell lung cancer,” Annals of Thoracic Surgery, vol. 91, no. 4, pp. 1059–1065, 2011.
[15]
A. Takise, T. Kodama, Y. Shimosato, S. Watanabe, and K. Suemasu, “Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter,” Cancer, vol. 61, no. 10, pp. 2083–2088, 1988.
[16]
T. Kurokawa, Y. Matsuno, M. Noguchi, S. Mizuno, and Y. Shimosato, “Surgically curable “early” adenocarcinoma in the periphery of the lung,” American Journal of Surgical Pathology, vol. 18, no. 5, pp. 431–438, 1994.
[17]
R. Maeda, J. Yoshida, G. Ishii, T. Hishida, M. Nishimura, and K. Nagai, “Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification,” Chest, vol. 140, no. 6, pp. 1494–1502, 2011.
[18]
Y. Shimada, H. Saji, K. Yoshida, et al., “Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage IA non-small-cell lung cancer after complete surgical resection,” Journal of Thoracic Oncology, vol. 7, no. 8, pp. 1263–1270, 2012.
[19]
N. Kobayashi, S. Toyooka, J. Soh et al., “Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20?mm or less,” Journal of Thoracic Oncology, vol. 2, no. 9, pp. 808–812, 2007.
[20]
M. Harada, T. Hato, and H. Horio, “Intratumoral lymphatic vessel involvement is an invasive indicator of completely resected pathologic stage i non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 6, no. 1, pp. 48–54, 2011.
[21]
K. Miyoshi, S. Moriyama, T. Kunitomo, and S. Nawa, “Prognostic impact of intratumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer,” Journal of Thoracic and Cardiovascular Surgery, vol. 137, no. 2, pp. 429–434, 2009.
[22]
A. Sayar, A. Turna, O. Solak, A. Kili?gün, N. ürer, and A. Gürses, “Nonanatomic prognostic factors in resected nonsmall cell lung carcinoma: the importance of perineural invasion as a new prognostic marker,” Annals of Thoracic Surgery, vol. 77, no. 2, pp. 421–425, 2004.
[23]
M. D. Taylor, A. S. Nagji, C. M. Bhamidipati, et al., “Tumor recurrence after complete resection for non-small cell lung cancer,” Annals of Thoracic Surgery, vol. 93, no. 6, pp. 1813–1820, 2012.
[24]
E. S. Kim, I. J. Lee, Y.-A. Bae, J.-W. Lee, H. J. Im, and Y. H. Jeon, “Evaluation of factors relating to tumor recurrence and survival after resection of lung cancer,” Acta Radiologica, vol. 50, no. 8, pp. 876–883, 2009.